Crystallization of recombinant Leishmania major pteridine reductase 1 (PTR1)
UMass Chan Affiliations
Department of Pharmacology and Molecular ToxicologyGraduate School of Biomedical Sciences
Document Type
Journal ArticlePublication Date
1999-09-18Keywords
Animals; Bacterial Proteins; Crystallization; Leishmania major; Oxidoreductases; Recombinant Proteins; X-Ray DiffractionLife Sciences
Medicine and Health Sciences
Metadata
Show full item recordAbstract
The enzyme pteridine reductase (PTR1) has recently been discovered in the protozoan parasite Leishmania and validated as a target for therapeutic intervention. PTR1 is responsible for the salvage of pteridines and also contributes to antifolate drug resistance. Structural analysis, in combination with ongoing biochemical characterization will assist the elucidation of the structure-activity relationships of this important enzyme and support a structure-based approach to discover novel inhibitors. Recombinant L. major PTR1 has been purified from an Escherichia coli expression system and used in crystallization experiments. Orthorhombic crystals have been obtained and data to 2.8 A has been measured. The space group is P2(1)2(1)2 or P2(1)2(1)2(1) with unit-cell dimensions of a = 103.9, b = 134.7, c = 96.2 A. One homotetramer, of molecular mass approximately 120 kDa, probably constitutes the asymmetric unit and gives a Matthews coefficient, V(m), of 2.8 A(3) Da(-1) and 56% solvent volume. Self-rotation function calculations show a single well defined non-crystallographic twofold axis with features that might represent additional elements of non-crystallographic symmetry. The detail of exactly what constitutes the asymmetric unit will be resolved by structure determination.Source
Acta Crystallogr D Biol Crystallogr. 1999 Sep;55(Pt 9):1608-10.
DOI
10.1107/S0907444999008999Permanent Link to this Item
http://hdl.handle.net/20.500.14038/33743PubMed ID
10489462Related Resources
ae974a485f413a2113503eed53cd6c53
10.1107/S0907444999008999